← Eichor
Condition: Hpv Positive Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hpv Positive Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
Phase 2 · 2 location(s) · Icahn School of Medicine at Mount Sinai · NCT05419089De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers
NA · 1 location(s) · Georgetown University · NCT06554158Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Phase N/A · 1 location(s) · Institut Pasteur du Cambodge · NCT07358910De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Phase 2 · 3 location(s) · Mayo Clinic · NCT05541016BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07209189Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Phase 2 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06323460Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receivi
NA · 2 location(s) · Georgetown University · NCT06902623Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05172245Digital Telecytology for Triage of HPV-Positive Women in Cameroon
NA · 2 location(s) · University Hospital, Geneva · NCT07550010A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06984861A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Meta
Phase 2 · 25 location(s) · Regeneron Pharmaceuticals · NCT06769698Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Phase 1 · 1 location(s) · Therorna · NCT07081984Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT05918510Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3 · 1 location(s) · Shanghai Bovax Biotechnology Co., Ltd. · NCT04422366A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05491512Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Phase 2 · 5 location(s) · University of Maryland, Baltimore · NCT06088381Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/Phase 2 · 17 location(s) · Nykode Therapeutics ASA · NCT06016920HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
Phase 1 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT04131413Oropharynx (OPX) Biomarker Trial
Phase N/A · 1 location(s) · Mayo Clinic · NCT06356272Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00867269De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas
NA · 10 location(s) · Technische Universität Dresden · NCT03396718Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · 100 location(s) · National Cancer Institute (NCI) · NCT07195734Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
Phase 2 · 1 location(s) · NYU Langone Health · NCT03215719A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papil
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT05307939Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest
Phase 2 · 1 location(s) · Mayo Clinic · NCT06997068CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
Phase 2 · 1 location(s) · Yale University · NCT07172256A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07063212ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
NA · 2 location(s) · Indiana University · NCT06915038
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.